SG11201903573RA - Antibody specifically binding to pauf protein and use thereof - Google Patents

Antibody specifically binding to pauf protein and use thereof

Info

Publication number
SG11201903573RA
SG11201903573RA SG11201903573RA SG11201903573RA SG11201903573RA SG 11201903573R A SG11201903573R A SG 11201903573RA SG 11201903573R A SG11201903573R A SG 11201903573RA SG 11201903573R A SG11201903573R A SG 11201903573RA SG 11201903573R A SG11201903573R A SG 11201903573RA
Authority
SG
Singapore
Prior art keywords
pauf
specifically binding
protein
present
antibody specifically
Prior art date
Application number
SG11201903573RA
Inventor
Sang Seok Koh
Yeon Jeong Kim
So Eun Youn
Song Cheol Kim
Seung-Mo Hong
Seong Yun Jeong
Original Assignee
Univ Dong A Res Found For Ind Acad Coop
Prestige Biopharma Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dong A Res Found For Ind Acad Coop, Prestige Biopharma Pte Ltd filed Critical Univ Dong A Res Found For Ind Acad Coop
Publication of SG11201903573RA publication Critical patent/SG11201903573RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to an anti body specifically binding to a pancreatic adenocarcinoma upregulated factor (PAUF) protein and use thereof. The antibody of the present invention binds to a PAUF protein with high specificity and affinity and thereby inhibits the pr oliferation, migration, invasion, and in vivo growth, and thus the antibody of the present invention can be e ffectively used in the field of diagnosis and treatment of diseases such as cancer in which PAUF proteins are overexpressed.
SG11201903573RA 2017-07-28 2017-08-16 Antibody specifically binding to pauf protein and use thereof SG11201903573RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170096370A KR101856904B1 (en) 2017-07-28 2017-07-28 Antibody specifically binding to PAUF and use thereof
PCT/KR2017/008893 WO2019022281A1 (en) 2017-07-28 2017-08-16 Antibody specifically binding to pauf protein, and use thereof

Publications (1)

Publication Number Publication Date
SG11201903573RA true SG11201903573RA (en) 2019-05-30

Family

ID=62185493

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903573RA SG11201903573RA (en) 2017-07-28 2017-08-16 Antibody specifically binding to pauf protein and use thereof

Country Status (18)

Country Link
US (1) US11046779B2 (en)
EP (1) EP3660052A4 (en)
JP (1) JP7017581B2 (en)
KR (1) KR101856904B1 (en)
CN (1) CN110291110B (en)
AR (1) AR112579A1 (en)
AU (1) AU2017425111B2 (en)
BR (1) BR112019010687A2 (en)
CA (1) CA3044216C (en)
IL (1) IL266576B2 (en)
MX (1) MX2020001027A (en)
MY (1) MY192517A (en)
PH (1) PH12020500172A1 (en)
RU (1) RU2735102C1 (en)
SG (1) SG11201903573RA (en)
TW (1) TWI703155B (en)
WO (1) WO2019022281A1 (en)
ZA (1) ZA202001042B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100954322B1 (en) * 2006-06-14 2010-04-21 주식회사 엘지생명과학 Gene familyLBFL313 associated with pancreatic cancer
WO2010036031A2 (en) * 2008-09-23 2010-04-01 Korea Research Institute Of Bioscience And Biotechnology Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
EP2703001A1 (en) * 2012-08-26 2014-03-05 XAX Kft. Tumor vaccination
KR101504039B1 (en) * 2012-11-16 2015-03-19 강원대학교산학협력단 Antibody specifically binding to L1CAM in humans and mice, and use thereof
WO2019022274A1 (en) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Antibody specifically binding to pauf protein, and use thereof

Also Published As

Publication number Publication date
IL266576B2 (en) 2024-06-01
ZA202001042B (en) 2021-05-26
MX2020001027A (en) 2020-08-06
IL266576A (en) 2019-07-31
JP7017581B2 (en) 2022-03-03
CA3044216A1 (en) 2019-01-31
EP3660052A1 (en) 2020-06-03
TW201910350A (en) 2019-03-16
KR101856904B1 (en) 2018-05-11
US11046779B2 (en) 2021-06-29
CA3044216C (en) 2023-05-23
CN110291110B (en) 2023-11-24
MY192517A (en) 2022-08-25
PH12020500172A1 (en) 2020-10-12
CN110291110A (en) 2019-09-27
JP2020520230A (en) 2020-07-09
BR112019010687A2 (en) 2020-02-18
AU2017425111B2 (en) 2020-06-18
AU2017425111A1 (en) 2019-05-16
IL266576B1 (en) 2024-02-01
AR112579A1 (en) 2019-11-13
RU2735102C1 (en) 2020-10-28
EP3660052A4 (en) 2021-04-14
US20200055951A1 (en) 2020-02-20
TWI703155B (en) 2020-09-01
WO2019022281A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
ZA202006859B (en) Antibodies specific for gucy2c and uses thereof
MX2019010972A (en) High affinity mage-a1-specific tcrs and uses thereof.
MX2019005911A (en) Novel anti_cd137 antibodies and uses thereof.
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
MX2018009011A (en) Anti-ror1 antibodies and uses thereof.
EA201892548A1 (en) ANTIBODIES TO ALPHA-SINUCULINE AND THEIR APPLICATION
MX360497B (en) Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof.
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EA201591072A1 (en) ANTIBODIES AGAINST PDGFR-BETA AND THEIR APPLICATIONS
MX2017001599A (en) Novel antibodies and uses thereof.
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
PH12016500425A1 (en) Il-18 binding protein (il-18bp) in inflammatory diseases
UA114277C2 (en) Anti-angiogenesis therfpy for the treatment of ovarian cancer
ECSP12012194A (en) BINDING PROTEINS DLL4 THERAPEUTICS
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
EA201790341A1 (en) ANTI-CK8 ANTIBODIES FOR USE IN TREATMENT OF CANCER
MX2018009499A (en) Egfl6 specific monoclonal antibodies and methods of their use.
MX2020001287A (en) Braf-specific tcrs and uses thereof.
MX2021011040A (en) Antibodies targeting c5ar.
BR112016023011A2 (en) gastric cancer treatment
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
MX2021015501A (en) Antibodies and methods of use.
SG11201903573RA (en) Antibody specifically binding to pauf protein and use thereof